Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Read more about Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Cabozantinib: An evolving therapy for hepatocellular carcinoma. Read more about Cabozantinib: An evolving therapy for hepatocellular carcinoma.
Management of locally recurrent nasopharyngeal carcinoma. Read more about Management of locally recurrent nasopharyngeal carcinoma.
The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Read more about The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going?
A clinician's guide to biosimilars in oncology. Read more about A clinician's guide to biosimilars in oncology.
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Read more about Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Read more about Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Read more about Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by Read more about Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer. Read more about Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer.
